Cardiology Research Institute, Tomsk National Research Medical Centre, Tomsk.
Siberian State Medical University, Tomsk.
Kardiologiia. 2021 Sep 30;61(9):33-39. doi: 10.18087/cardio.2021.9.n1528.
Aim To reveal a relationship between preprocedural laboratory data and adverse cardiac outcomes (CO) in patients with stable ischemic heart disease (IHD) following elective endovascular revascularization (ER).Material and methods This study included 225 patients with IHD admitted for treatment to the Research Institute of Cardiology of the Tomsk National Research Medical Center. The study included patients with documented IHD and hemodynamically significant coronary stenoses requiring elective ER. Patients were divided into groups based on the presence of complications: group 1, 98 patients with adverse CO and group 2, 127 patients without adverse CO. Besides evaluation of complaints, history, and objective status, general clinical and biochemical tests were performed for all patients. Concentration of glycated hemoglobin (НbА1с) was measured by immunoturbidimetry (DiaSys Diagnostic Systems). Serum concentrations of insulin, interleukin-6 (IL-6), endothelin 1 (ET-1), and homocysteine were measured by enzyme immunoassay. Blood lipid profile was determined by enzymatic colorimetry (DiaSys). Content of non-high-density lipoprotein (non-HDL) cholesterol (CS) was calculated as: CS - HDL CS. Insulin resistance (IR) was assessed by the HOMА-IR index. IR was diagnosed at the index of 2.77. Statistical analyses were performed with Statistica 10.0 and Medcalc 19.2.6 software.Results A one-way regression analysis identified predictors for adverse CO following ER. The most significant predictors were fibrinogen (odds ratio (OR), 1.430; 95 % confidence interval (CI), 1.027-1.990), HbA1c (OR 1.825; 95 % CI, 1.283-2.598), homocysteine (OR, 1.555; 95 % CI, 1.348-1.794), ET-1 (OR, 94.408; 95 % CI, 16.762-531.720), triglycerides (TG)/glucose ratio (OR 1.815; 95 % CI, 1.155-2.853). Based on selected factors, logistic regression models were constructed. However, not all models had a high prognostic power. Only concentrations of ET-1 and homocysteine showed a high prognostic capability in respect of the adverse outcome (88.3 and 85.7 %, respectively).Conclusion For patients with IHD, the prognostic capability of ET-1 and homocysteine with respect of the risk for adverse CO following ER was the highest compared to other markers. The results of the study are completely consistent with data of literature and can be successfully used in clinical practice for optimizing the medical care of patients after elective ER.
揭示择期血管内血运重建(ER)后稳定型缺血性心脏病(IHD)患者术前实验室数据与不良心脏结局(CO)之间的关系。
本研究纳入了 225 名因 IHD 住院接受治疗的托姆斯克国家研究医疗中心心血管病研究所患者。该研究纳入了有记录的 IHD 且需要择期 ER 治疗的有血流动力学意义的冠状动脉狭窄患者。根据是否存在并发症将患者分为两组:第 1 组 98 例患者发生不良 CO,第 2 组 127 例患者未发生不良 CO。除了评估症状、病史和客观状态外,还对所有患者进行了一般临床和生化检查。通过免疫比浊法(DiaSys 诊断系统)测量糖化血红蛋白(HbA1с)的浓度。通过酶免疫测定法测量胰岛素、白细胞介素-6(IL-6)、内皮素 1(ET-1)和同型半胱氨酸的血清浓度。通过酶比色法(DiaSys)测定血脂谱。非高密度脂蛋白(non-HDL)胆固醇(CS)含量计算为:CS-HDL CS。通过 HOMА-IR 指数评估胰岛素抵抗(IR)。IR 诊断指数为 2.77。统计分析使用了 Statistica 10.0 和 Medcalc 19.2.6 软件。
单向回归分析确定了 ER 后不良 CO 的预测因子。最显著的预测因子是纤维蛋白原(比值比(OR),1.430;95%置信区间(CI),1.027-1.990)、HbA1c(OR 1.825;95%CI,1.283-2.598)、同型半胱氨酸(OR,1.555;95%CI,1.348-1.794)、ET-1(OR,94.408;95%CI,16.762-531.720)、甘油三酯(TG)/葡萄糖比值(OR,1.815;95%CI,1.155-2.853)。基于选定的因素,构建了逻辑回归模型。然而,并非所有模型都具有较高的预测能力。只有 ET-1 和同型半胱氨酸的浓度对不良结局具有较高的预测能力(分别为 88.3%和 85.7%)。
对于 IHD 患者,与其他标志物相比,ET-1 和同型半胱氨酸对 ER 后不良 CO 风险的预测能力最高。研究结果与文献数据完全一致,可成功用于临床实践,以优化择期 ER 后患者的医疗护理。